Transcarotid neurovascular catheter

Information

  • Patent Grant
  • 11291799
  • Patent Number
    11,291,799
  • Date Filed
    Monday, August 19, 2019
    4 years ago
  • Date Issued
    Tuesday, April 5, 2022
    2 years ago
Abstract
An interventional catheter for treating an artery includes an elongated body sized and shaped to be transcervically introduced into a common carotid artery at an access location in the neck. The elongated body has an overall length such that the distal most section can be positioned in an intracranial artery and at least a portion of the proximal most section is positioned in the common carotid artery during use.
Description
BACKGROUND

Intravascular catheters are used to access target vascular regions from remote vascular access sites to perform a procedure. The design, materials, and construction of particular catheters are primarily directed to allow the catheter to reach the target vascular anatomy while not causing vessel trauma, as well as to perform the catheter's intended function upon the catheter reaching the target anatomy. The catheter often has multiple requirements that may conflict with one another. Consequently, a strong design optimally balances the goals of these requirements.


Many catheters are single lumen catheters wherein the lumen acts as a channel for the delivery of radiopaque or therapeutic agents or for other interventional devices into the blood vessel, and/or for aspiration of blood, thrombus, or other occlusive material out of the blood vessel. Such catheters have physical properties that allow them to be advanced through a vessel access site from a proximal end into vascular anatomy which is often very curved, delicate, tortuous, and remote from the blood vessel access site. These catheters are also designed to be used with adjunctive devices such as guide wires and sometimes smaller catheters positioned in the inner lumen, and to be directed to the target anatomy through vascular access sheaths, guide catheters and sometimes sub-selective guide catheters (i.e. catheters that are specifically designed to go to more distal locations than typical guide catheters). In other words, it is often not a single catheter but a system of catheters, guide wires, guide catheters, and sheaths that allows the user to adequately perform an intended procedure.


Interventions in the cerebral vasculature often have special access challenges. Most neurointerventional procedures use a transfemoral access to the carotid or vertebral artery and thence to the target cerebral artery. However, this access route is often tortuous and may contain stenosic plaque material in the aortic arch and carotid and brachiocephalic vessel origins, presenting a risk of embolic complications during the access portion of the procedure. In addition, the cerebral vessels are usually more delicate and prone to perforation than coronary or other peripheral vasculature. In recent years, interventional devices such as wires, guide catheters, stents and balloon catheters, have all been scaled down and been made more flexible to better perform in the neurovascular anatomy. However, many neurointerventional procedures remain either more difficult or impossible because of device access challenges. In some instances, a desired access site is the carotid artery. Procedures in the intracranial and cerebral arteries are much closer to this access site than a femoral artery access site. Importantly, the risk of embolic complications while navigating the aortic arch and proximal carotid and brachiocephalic arteries are avoided. However, because most catheters used in interventional procedures are designed for a femoral access site, current devices are not ideal for the alternate carotid access sites, both in length and mechanical properties. This makes the procedure more cumbersome and in some cases more risky if using devices designed for femoral access in a carotid access procedure.


U.S. Pat. No. 5,496,294 (the '294 patent) describes a single lumen, three-layer catheter design, including (1) an inner Polytetrafluoroethylene (PTFE) liner to provide a low-friction inner surface; (2) a reinforcement layer formed of a metal coil wire or coil ribbon; and (3) an outer jacket layer. Typically, the three layers are laminated together using heat and external pressure such as with heat shrink tubing. The catheter has multiple sections of varying stiffness such that flexibility increases moving towards the distal end of the catheter. This variation in flexibility may be accomplished by varying the durometer of the outer jacket layer along the length of the catheter. Another method to vary flexibility is by varying the reinforcement structure and/or material along the length of the catheter.


One limitation in the '294 patent and in other existing neurovascular catheter technology is that the devices are designed for a femoral access approach to the cerebral arteries. The pathway from the femoral artery to the common carotid artery and thence to the internal carotid artery is both long and comprises several back and forth bends. The dimensions provided in the '294 patent are consistent with this design goal. However, catheters designed to navigate this route have lengths and flexibility transitions that would not be appropriate for a transcarotid access, and would in fact detract from performance of a transcarotid catheter. For example the flexible sections must be at least 40 cm of gradually increasing stiffness from the distal end to a proximal-most stiff section, to be able to navigate both the internal carotid artery curvature and the bends required to go from the aortic arch into the common and then the internal carotid artery.


Another disadvantage to the catheter construction described in the '294 patent is the catheter's limited ability to have continuous, smooth transitions in flexibility moving along its length. There are discreet differences in flexibility on a catheter where one jacket material abuts another, or when one reinforcement structures abuts another reinforcement structure. In addition, the tri-layer catheter construction of the '294 patent has limitations on the wall-thickness due to the need to be able to handle and assemble the three layers of the catheter during manufacture. In addition, the catheter construction makes it difficult to have a relatively large inner lumen diameter while maintaining properties of flexibility and/or kink resistance to very sharp bends in the blood vessel. As a general rule, the larger diameter catheters also tend to be stiffer in order to remain kink resistant.


SUMMARY

There is a need for a catheter with dimensions and mechanical properties which have been optimized to access the cerebral vessels from a carotid artery access site. There is also a need to for a catheter that has gradual, smooth transitions from a first flexibility to at least a second, different flexibility moving along the length of the catheter. There is also a need for a catheter that has a relatively large inner diameter compared to prior art catheters, and yet is able to maintain physical properties such as thin wall thickness, kink resistance and flexibility.


Disclosed is an intravascular catheter that that has been optimized for accessing anterior cerebral vessels from a carotid artery access site.


Disclosed also is a catheter which includes variations in flexibility or stiffness moving along at the entire length of catheter or a portion of the length of the catheter. Advantageously, the change in flexibility of the catheter is represented by smooth, rather than sudden, changes in flexibility. In other words, the flexibility of the catheter transitions gradually moving along its length without any sudden or discrete variations in flexibility from one section of the catheter to an adjacent section of the catheter. As described in more detail below, the catheter can be particularly sized and shaped according to how the catheter will be used and in what particular section of the vascular anatomy the catheter will be used.


Also disclosed is an interventional catheter for treating an artery, comprising: an elongated body sized and shaped to be transcervically introduced into a common carotid artery at an access location in the neck, the elongated body sized and shaped to be navigated distally to an intracranial artery through the common carotid artery via the access location in the neck; an internal lumen in the elongated body, the internal lumen forming a proximal opening in a proximal region of the elongated body and a distal opening in a distal region of the elongated body; wherein the elongated body has a proximal most section and a distal most section wherein the proximal most section is a stiffest portion of the elongated body, and wherein the elongated body has an overall length and a distal most section length such that the distal most section can be positioned in an intracranial artery and at least a portion of the proximal most section is positioned in the common carotid artery during use.


Other features and advantages should be apparent from the following description of various embodiments, which illustrate, by way of example, the principles of the disclosure.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A shows a schematic view of an exemplary catheter.



FIG. 1B shows a schematic view of an alternate embodiment of a catheter.



FIGS. 2-5 show examples of catheters having angled distal tips or distal edges.



FIG. 6 illustrates an embodiment of a catheter with a tapered co-axial inner member.



FIG. 7 illustrates another embodiment of a catheter with a tapered co-axial inner member.





DETAILED DESCRIPTION


FIG. 1A shows a schematic view of an exemplary catheter 105. The catheter 105 is an elongated body that has an external dimension that is sized and shaped for insertion into a blood vessel. In an embodiment, the catheter 105 is sized and shaped for insertion into an access sheath of a carotid artery access system such as described in U.S. patent application Ser. No. 12/834,869 entitled SYSTEMS AND METHODS FOR TREATING A CAROTID ARTERY, which is incorporated by reference herein in its entirety. U.S. patent application Ser. No. 14/537,316 entitled METHODS AND DEVICES FOR TRANSCAROTID ACCESS and filed Nov. 10, 2014 is also incorporated herein by reference in its entirety. The proximal region of the catheter 105 may have one or more mechanical or electro-mechanical control mechanisms for controlling different components on or near a distal end of the catheter 105. For example, the control mechanism(s) can be used to control inflation of a balloon or balloons, advancement/deployment of a system component (such as a stent), flushing or aspirating a fluid through the catheter, and combinations thereof.


With reference again to FIG. 1A, the catheter 105 is configured to be inserted through an access sheath in the carotid artery and navigated distally to the distal ICA or cerebral vessels. A proximal port 2035 with a hemostasis valve may be situated on the proximal end of catheter 105, to allow introduction of devices such as a microcatheter, guide wire, stent delivery device, aneurysm coil delivery device, or thrombectomy device while preventing or minimizing blood loss during the procedure. The hemostasis valve may be integral to the catheter proximal adaptor, or may be removably attached to the proximal end of the catheter via a proximal connector. In an embodiment, this valve is an adjustable-opening valve such as a Tuohy-Borst or rotating hemostasis valve (RHV). In another embodiment, the valve is a passive seal hemostasis valve.


The catheter 105 may be made with a two or more layer construction. In an embodiment, the catheter has a PTFE inner liner, an outer jacket layer, and at least a portion of the catheter has a reinforcement structure, such as a tubular structure formed of, for example, a wound coil, braid or cut hyptotube. In addition, the catheter may have a radiopaque marker at the distal tip to facilitate placement of the device using fluoroscopy.


The catheter 105 has an insertable portion (or working length) that is sized to be inserted through an access sheath in the carotid artery and passed through an arterial pathway (through the artery) to the distal ICA or cerebral vessels. In an embodiment adapted to be used with an access sheath of total length including the sheath hemostasis valve of about 15 to 20 cm, the catheter 105 has a working length ranging from 40 to 70 cm. The working length (or insertable portion) of the catheter is the portion of the catheter that is sized and shaped to be inserted into the artery and wherein at least a portion of the working length is actually inserted into the artery during a procedure. In an embodiment, the catheter has a working length of less than 70 cm, less than 60 cm, or less than 50 cm. A similar catheter designed for a transfemoral access site may have a working length of between 100 and 130 cm. Alternately, the length of catheter can be defined relative to the location of the access site and the target cerebral artery site. In an embodiment, the catheter is configured to be introduced into the artery at a location in the artery that is less than 40 cm, less than 30 cm, or less than 20 cm from the location of the target site as measured through the arterial pathway. The distance may further be defined by a ratio of working length to the distance between the location where the catheter enters the arteriotomy and the target site. In an embodiment, this ratio is less than 2×. In an embodiment, the working length of the device may have a hydrophilic coating to improve the ease of advancement of the device through the vasculature. In an embodiment, at least 40% of the working length of the catheter is coated with a hydrophilic material. In other embodiments, at least 50% or at least 60% of the working length of the catheter is coated with a hydrophilic material. In an embodiment, the elongated body has an overall length and a distal most section or portion length such that the distal most section can be positioned in an intracranial artery and at least a portion of the proximal most section 115 (FIG. 1A) is positioned in the common carotid artery during use while transcervically inserted into the common carotid artery.


In an embodiment, the distal-most section 111 (FIG. 1A) is constructed to be more flexible than the proximal portion, with one or more flexible sections, to successfully navigate the internal carotid artery curvature to reach target sites in the distal (internal carotid artery) ICA or cerebral arteries. The shaft may have a transition, or intermediate, section 113 of one or more increasingly stiff sections towards the more proximal section of the shaft, with the proximal most portion having the stiffest shaft section. Alternately, the transition section is a section of continuously variable stiffness from the distal section stiffness to the proximal section stiffness. In an embodiment, the distal most flexible section is between 5 and 15 cm. In another embodiment, the distal most flexible section is between 3 and 10 cm. In another embodiment, the distal section is between 2 and 7 cm. In an embodiment, the transition section is between 5 and 15 cm. In another embodiment, the transition section is between 5 and 10 cm. In another embodiment, the transition section is between 4 and 8 cm. In all these embodiments, the proximal-most stiff section takes up the remainder of the working length. In an embodiment where the catheter has a working length of 40 cm, the proximal-most stiff section is in a range 10 to 30 cm. In an embodiment where the catheter has a working length of 70 cm, the proximal-most stiff section is in a range from 40 to 60 cm. In an embodiment, the stiffest portion of the catheter is the proximal most portion of the catheter. The catheter can have a length such that, when inserted into the common carotid artery via a transcarotid entryway into the artery, the stiffest section of the catheter is located at least partially within the common carotid artery or can be positioned at least two centimeters into the common carotid artery. In an embodiment, the catheter has a length such that at least portion of the proximal most section is positioned in the common carotid artery when the distal most section is in an intracranial artery during use. The relative lengths of distal most section, transition section, and proximal most sections are not necessarily shown to scale in FIG. 1A.


Alternately, the flexible distal section and transition section may be described as a portion of the overall catheter working length. In an embodiment, the flexible distal most section is between 3 to 15% of the length of the working length of the catheter. In another embodiment, the flexible distal most section is between 4 and 25% of the length of the working length of the catheter. Similarly, in an embodiment, the transition section is between 7 and 35% of the length of the working length of the catheter. In another embodiment, the transition section is between 6 and 20% of the working length of the catheter.


In an embodiment, the flexibility of the distal most section is in the range 3 to 10 N-mm2 and the flexibility of the proximal post section is in the range 100 to 500 N-mm2, with the flexibility/flexibilities of the transition section falling between these two values.


As noted above, the catheter may have sections with discreet and/or continuously variable stiffness shaft. The sections of varying flexibility may be achieved by multiple methods. For example, the outer jacket layer may be composed of discreet sections of polymer with different durometers, composition, and/or thickness. In another embodiment, the outer layer has one or more sections of continuously variable outer layer material that varies in flexibility. The catheter may be equipped with the continuously variable outer layer material by dip coating the outer layer rather than laminating a jacket extrusion onto a PTFE-liner and reinforcement assembly of the catheter. The dip coating may be, for example, a polymer solution that polymerizes to create the outer jacket layer of the catheter. The smooth transition from one flexibility (e.g., durometer) to another flexibility along the length of the catheter can be accomplished via dipping the catheter assembly in multiple varying durometer materials whereby the transition from one durometer to another can be accomplished in a graded pattern, for example by dipping from one side of the catheter in one durometer with a tapering off in a transition zone, and dipping from the other side in another durometer with a tapering off in the same transition zone, so there is a gradual transition from one durometer to the other. In this embodiment, the dip coating can create a thinner walled outer jacket than a lamination assembly. In another embodiment, the catheter has an outer jacket layer that is extruded with variable durometer along the length, to provide variable flexibility along the length of the catheter.


In an embodiment, at least a portion of the catheter has a reinforcement structure, such as a tubular structure formed of, for example, a wound coil, braid that is composed of discreet or continuously varying structure to vary the stiffness, for example a variable coil or braid pitch. In an embodiment, the reinforcement structure is a cut hyptotube, with a cut pattern that is graded along the length, for example cut in a spiral pattern with continuously variable pitch or continually variable cut gap, or a repeating cut pattern that allows the tube to flex whereby the repeating pattern has a continuously variable repeat distance or repeat size or both. A cut hypotube-reinforced catheter may also have superior pushability than a coil-reinforced catheter, as it is a structure with potentially greater stability in the axial direction than a wound coil. The material for the reinforcement structure may be stainless steel, for example 304 stainless steel, nitinol, cobalt chromium alloy, or other metal alloy that provides the desired combination of strengths, flexibility, and resistance to crush. In an embodiment, the reinforcement structure comprises multiple materials along the different sections of flexibility.


In another embodiment the catheter has a PTFE inner liner with one or more thicknesses along variable sections of flexibility. In an embodiment, the PTFE inner liner is constructed to be extremely thin, for example between 0.0005″ and 0.0010″. This embodiment provides the catheter with a high level of flexibility as well as the ability to construct a thinner-walled catheter. For example, the PTFE liner is constructed by drawing a mandrel through a liquid PTFE liquid solution rather than the conventional method of thin-walled PTFE tubing manufacture, namely extrusion of a PTFE paste which is then dried and sintered to create a PTFE tube. The draw method allows a very thin and controlled wall thickness, such as in the range of 0.0005″-0.0010″.


Any one of the aforementioned manufacturing methods may be used in combination to construct the desired flexibility and kink resistance requirement. Current tri-layer catheters have wall thicknesses ranging from 0.005″ to 0.008″. These manufacturing techniques may results in a catheter with better catheter performance at the same wall thickness, or with equal or better catheter performance at lower wall thicknesses for example between 0.003″ to 0.005″.


In an embodiment, the distal flexible section of the catheter may be constructed using one or more of: a dip coated outer layer, an extremely thin drawn PTFE layer, and a cut hypotube reinforcement layer, with a gradual transition from the flexible section to a stiffer proximal section. In an embodiment, the entire catheter is constructed with one or more of these elements.


In some instances, there is a need to reach anatomic targets with the largest possible internal lumen size for the catheter. For example the catheter may be used to aspirate an occlusion in the blood vessel. Thus there is a desire to have a very flexible, kink resistant and collapse resistant catheter with a thin wall and large inner diameter. A catheter using the construction techniques disclosed herein meets these requirements. For example, the catheter may have an inner diameter of 0.068″ to 0.095″ and a working length of 40-60 cm. In another embodiment, the catheter may be sized to reach the more distal cerebral arteries, with an inner diameter of 0.035″ to 0.062″ and a working length of 50-70 cm. In an embodiment, the catheter is configured to navigate around a 180° bend around a radius as small as 0.050″ or 0.100″ without kinking, wherein the bends are located within 5 cm, 10 cm, or 15 cm of the arteriotomy measured through the artery. In an embodiment, the catheter can resist collapsing whilst in a tortuous anatomy up to 180°×0.050″ radius bend without collapsing when connected to a vacuum up to 20 inHg. In an embodiment, the catheter can resist collapse in the same conditions when connected to a vacuum up to 25 inHg.


In another embodiment shown in FIG. 1B, the inner and outer diameter may be stepped up at a proximal region 107 of the catheter. The step up corresponds to an increase in diameter relative to an adjacent region of the catheter. This embodiment would further optimize the aspiration power of the catheter. For example, the portion of the catheter which is in more proximal, larger vessels during a procedure may have a larger diameter than distal region 109 of the catheter, which can be the distal most region. In this embodiment, the catheter may have a diameter for the region 109 (such as the distal most 10-15 cm), then have a step up in diameter of between 10-25% of the distal most diameter for the proximal region 107 of the working length. The step up would occur over a tapered transition section between 3 and 10 mm in length, depending on the size of the step up and the need to make a smooth transition. Alternately, the catheter is used with a stepped sheath with a larger diameter proximal region. In this case, the catheter may be stepped up a length and diameter to match the stepped sheath. For example, if the sheath has a portion with larger diameter for the proximal 20 cm of the sheath, the catheter would have a larger diameter for the proximal 25 cm to allow for additional length through proximal adaptors and valves such as an RHV. The remaining distal region would have a smaller diameter, with a step up over a tapered transition section between 3 and 10 mm in length, depending on the size of the step up and the need to make a smooth transition.


In some instances, a neurovascular catheter is used to aspirate clot or other obstruction in a cerebral or intracranial vessel. FIGS. 2-5 show examples of catheters having angled distal tips or distal edges. With reference to FIG. 2, the distal region of a catheter 105 is shown. The catheter 105 has a distal-most tip or edge 210 that forms an opening 215 at the distal end of the catheter 105. The distal edge 210 forms an angle that is non-perpendicular relative to the longitudinal axis L. Such a tip defines a different sized opening 215 than if the tip were perpendicular to the axis L. That is, the opening 215 is larger and presents a larger suction area relative to a distal tip that is cut normal to the longitudinal axis. The catheter therefore may provide a larger suction force on the occlusion located near the tip. The larger area opening 215 also facilitates suctioning the clot into the lumen of the catheter, rather than just capturing the clot at the tip with suction force and pulling back the captured clot with the catheter. In FIG. 2, the catheter 105 has an angled, straight edge 210 creating an elliptical opening 215. In FIGS. 3, 4 and 5, the distal edge 210 is curved or non-straight such that the distal opening 215 is non-planar and may offer greater opening without extending the tip length out as much, which may optimize the contact area with the occlusion further. The distal edge 210 may be straight, curved, undulating, or irregular. In an embodiment with a cut hypotube-reinforced catheter, the distal tip of the hypotube can be formed with the non-square shape. In an embodiment with a radiopaque marker band, the radiopaque marker band may have a non-square edge which can then be used to create the non-square catheter tip shape. In an embodiment, the catheter may have an angled distal tip. That is, the distal tip of the catheter is angled or non-perpendicular relative to a longitudinal axis of the catheter.


A cause of difficulty in advancing catheters through severe bends and across side branches is the mismatch between the catheter and the inner guiding components such as smaller catheters, microcatheters, or guidewires. One technique for advancing a catheter is called a tri-axial technique in which a smaller catheter or microcatheter is placed between the catheter and the guide wire. However, with current systems the smaller catheter has a diameter mismatch between either the larger catheter, the guide wire, or both, which creates a step in the system's leading edge as the system is advanced in the vasculature. This step may cause difficulty when navigating very curved vessels, especially at a location where there is a side-branch, for example the ophthalmic artery. In an embodiment, as shown in FIG. 6, the catheter 105 is supplied with a tapered co-axial inner member 2652 that replaces the smaller catheter generally used. The inner member 2652 is sized and shaped to be inserted through the internal lumen of the catheter. The inner member 2652 has a tapered region with an outer diameter that forms a smooth transition between the inner diameter of the catheter 2030 and the outer diameter of a guidewire 2515 or microcatheter that extends through an internal lumen of the inner member 2652. In an embodiment, the tapered dilator or inner member 2652, when positioned within the catheter, creates a smooth transition between the distal-most tip of the larger catheter 105 and the outer diameter of a guide wire 2515 which may be in the range of 0.014″ and 0.018″ diameter for example. For example, the inner luminal diameter may be between 0.020″ and 0.024″. In another embodiment, the inner diameter is configured to accept a microcatheter with an outer diameter in the range of 0.030″ to 0.040″ or an 0.035″ guide wire in the inner lumen, for example the inner luminal diameter may be 0.042″ to 0.044″.


In a variation of this embodiment, shown in FIG. 7, in addition to the tapered region, the inner member 2652 includes an extension formed of a uniform diameter or a single diameter, distal-most region 2653 that extends distally past the tapered portion of the inner member 2652. In this embodiment the distal region 2653 of the inner member 2652 may perform some or all of the functions that a microcatheter would do during an interventional procedure, for example cross an occlusion to perform distal angiograms, inject intraarterial agents, or deliver devices such as aneurysm coils or stent retrievers. In this manner, a microcatheter would not need to be exchanged for the dilator for these steps to occur.


The material of the dilator (inner member 2652) is flexible enough and the taper is long enough to create a smooth transition between the flexibility of the guide wire and the catheter. This configuration will facilitate advancement of the catheter through the curved anatomy and into the target cerebral vasculature. In an embodiment, the dilator is constructed to have variable stiffness, for example the distal most section is made from softer material, with increasingly harder materials towards the more proximal sections. In an embodiment, distal end of the tapered dilator has a radiopaque marker such as a platinum/iridium band, a tungsten, platinum, or tantalum-impregnated polymer, or other radiopaque marker.


Although embodiments of various methods and devices are described herein in detail with reference to certain versions, it should be appreciated that other versions, embodiments, methods of use, and combinations thereof are also possible. Therefore the spirit and scope of the appended claims should not be limited to the description of the embodiments contained herein.

Claims
  • 1. An interventional catheter for treating an artery, comprising: an elongated body adapted to be inserted into a common carotid artery via an access location in the neck such that the elongated body can be navigated distally to an artery in a brain through the common carotid artery via the access location, the elongated body having an internal lumen, a proximal opening, and a distal opening, wherein the distal opening is formed by a distal edge of the catheter, and wherein the distal edge forms an angle that is non-perpendicular relative to a longitudinal axis of the elongated body;wherein the elongated body has a proximal most section and a distal most section, the proximal most section being a stiffest portion of the elongated body, and wherein the elongated body has an overall length such that the distal most section can be positioned in the artery in the brain while the proximal most section is positioned in the common carotid artery during use;wherein the distal most section of the catheter has an inner diameter of 0.035 to 0.062 inch;wherein the catheter can navigate around a 180° bend with a radius of 0.100″ without kinking; andwherein the catheter does not collapse when connected to a vacuum up to 25 inHg while navigating around a 180° bend with a radius of 0.100″.
  • 2. A catheter as in claim 1, wherein the elongated body has a working length and wherein the distal most section is between 4% and 25% of the length of the working length of the elongated body.
  • 3. A catheter as in claim 1, wherein the proximal most section has a stiffness in the range of 100 to 500 N-mm2.
  • 4. A catheter as in claim 1, wherein the distal most section has a stiffness in the range of 3 to 10 N-mm2.
  • 5. A catheter as in claim 1, wherein the distal most section is between 5 and 15 cm in length.
  • 6. A catheter as in claim 1, wherein the distal most section is between 3 and 10 cm in length.
  • 7. A catheter as in claim 1, wherein the elongated body has a working length of 40 cm and the proximal most section has a length of 10 to 30 cm.
  • 8. A catheter as in claim 1, further comprising an inner member inside the internal lumen, the inner member having a tapered leading edge.
  • 9. A catheter as in claim 1, wherein the elongated body includes a first transition section between the proximal section and the distal most section, and wherein the transition section has a stiffness between a stiffness of the proximal most section and the distal most section.
  • 10. A catheter as in claim 9, wherein the first transition section is 5 and 10 cm in length.
  • 11. A catheter as in claim 9, wherein the first transition section is 4 and 8 cm in length.
  • 12. A catheter as in claim 1, wherein the elongated body varies in stiffness moving along at least a portion of the length of catheter.
  • 13. A catheter as in claim 12, wherein the variation in stiffness is represented by smooth change in flexibility without any sudden changes in flexibility.
  • 14. A catheter as in claim 12, wherein the flexibility of the elongated body transitions gradually moving along its length without any discrete variations in flexibility from one section of the elongated body to an adjacent section of the elongated body.
  • 15. A catheter as in claim 1, wherein the elongated body has a working length and wherein the distal most section is between 3% and 15% of the length of the working length of the elongated body.
  • 16. A catheter as in claim 15, wherein the first transition section is between 7 and 35% of the length of the working length of the catheter.
  • 17. A catheter as in claim 15, wherein the first transition section is between 6 and 20% of the length of the working length of the catheter.
  • 18. A catheter as in claim 15, wherein the elongated body has an inner diameter of 0.068″ to 0.095″ and a working length of 40-60 cm.
  • 19. A catheter as in claim 15, wherein the elongated body has an inner diameter of 0.035″ to 0.062″ and a working length of 50-70 cm.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a Continuation of U.S. application Ser. No. 15/728,915 filed Oct. 10, 2017 entitled “Transcarotid Neurovascular Catheter” and issuing on Aug. 20, 2019 as U.S. Pat. No. 10,384,034, which is a Continuation of U.S. application Ser. No. 15/299,146, filed Oct. 20, 2016 now U.S. Pat. No. 9,861,783 entitled “Transcarotid Neurovascular Catheter”, which is a Continuation of U.S. application Ser. No. 15/050,039 filed Feb. 22, 2016 now U.S. Pat. No. 9,492,637 entitled “Transcarotid Neurovascular Catheter” which is a Continuation of U.S. application Ser. No. 14/569,365 filed Dec. 12, 2014, now U.S. Pat. No. 9,265,512 entitled “Transcarotid Neurovascular Catheter”, which claims priority to: (1) U.S. Provisional Application Ser. No. 62/029,799 filed Jul. 28, 2014; (2) U.S. Provisional Application Ser. No. 62/075,101 filed Nov. 4, 2014; (3) U.S. Provisional Application Ser. No. 62/046,112 filed Sep. 4, 2014; and (4) U.S. Provisional Application Ser. No. 62/075,169 filed Nov. 4, 2014; (5) U.S. Provisional Application Ser. No. 61/919,945 filed Dec. 23, 2013; and (6) U.S. Provisional Application Ser. No. 62/083,128 filed Nov. 21, 2014, which are hereby incorporated by reference in their entirety for all purposes.

US Referenced Citations (424)
Number Name Date Kind
3993079 Henriques de Gatztanondo Nov 1976 A
4354491 Marbry Oct 1982 A
4771777 Horzewski et al. Sep 1988 A
4840690 Melinyshyn et al. Jun 1989 A
4862891 Smith Sep 1989 A
4865581 Lundquist et al. Sep 1989 A
4921478 Solano et al. May 1990 A
4921479 Grayzel May 1990 A
4946440 Hall Aug 1990 A
5084022 Claude Jan 1992 A
5112308 Olsen et al. May 1992 A
5135484 Wright Aug 1992 A
5250060 Carbo et al. Oct 1993 A
5312356 Engelson et al. May 1994 A
RE34633 Sos et al. Jun 1994 E
5324262 Fischell et al. Jun 1994 A
5328471 Slepian Jul 1994 A
5380284 Don Michael Jan 1995 A
5429605 Richling Jul 1995 A
5437632 Engelson Aug 1995 A
5443454 Tanabe et al. Aug 1995 A
5454795 Samson Oct 1995 A
5456667 Ham et al. Oct 1995 A
5476450 Ruggio Dec 1995 A
5484412 Pierpont Jan 1996 A
5484418 Quiachon et al. Jan 1996 A
5492530 Fischell et al. Feb 1996 A
5496294 Hergenrother et al. Mar 1996 A
5522836 Palermo Jun 1996 A
5542937 Chee et al. Aug 1996 A
5558635 Cannon Sep 1996 A
5573520 Schwartz et al. Nov 1996 A
5599326 Carter Feb 1997 A
5628754 Shevlin et al. May 1997 A
5658264 Samson Aug 1997 A
5667499 Welch et al. Sep 1997 A
5695483 Samson Dec 1997 A
5702373 Samson Dec 1997 A
5707376 Kavteladze et al. Jan 1998 A
5730734 Adams et al. Mar 1998 A
5749849 Engelson May 1998 A
5749858 Cramer May 1998 A
5794629 Frazee Aug 1998 A
5795341 Samson Aug 1998 A
5810869 Kaplan et al. Sep 1998 A
5827229 Auth et al. Oct 1998 A
5833650 Imran Nov 1998 A
5836926 Peterson et al. Nov 1998 A
5836955 Buelna et al. Nov 1998 A
5846251 Hart Dec 1998 A
5851203 van Muiden Dec 1998 A
5851210 Torossian Dec 1998 A
5853400 Samson Dec 1998 A
5876367 Kaganov et al. Mar 1999 A
5876386 Samson Mar 1999 A
5882334 Sepetka et al. Mar 1999 A
5895399 Barbut et al. Apr 1999 A
5908407 Frazee et al. Jun 1999 A
5913848 Luther et al. Jun 1999 A
5916208 Luther et al. Jun 1999 A
5921952 Desmond, III et al. Jul 1999 A
5928192 Maahs Jul 1999 A
5935122 Fourkas et al. Aug 1999 A
5938645 Gordon Aug 1999 A
5957882 Nita et al. Sep 1999 A
5964773 Greenstein Oct 1999 A
5976093 Jang Nov 1999 A
5976178 Goldsteen et al. Nov 1999 A
5997508 Lunn et al. Dec 1999 A
6004310 Bardsley et al. Dec 1999 A
6013085 Howard Jan 2000 A
6022336 Zadno-Azizi et al. Feb 2000 A
6022340 Sepetka et al. Feb 2000 A
6030369 Engelson et al. Feb 2000 A
6033388 Nordstrom et al. Mar 2000 A
6044845 Lewis Apr 2000 A
6053903 Samson Apr 2000 A
6053904 Scribner et al. Apr 2000 A
6071263 Kirkman Jun 2000 A
6074357 Kaganov et al. Jun 2000 A
6074398 Leschinsky Jun 2000 A
6090072 Kratoska et al. Jul 2000 A
6110139 Loubser Aug 2000 A
6139524 Killion Oct 2000 A
6146370 Barbut Nov 2000 A
6146373 Cragg et al. Nov 2000 A
6146415 Fitz Nov 2000 A
6152909 Bagaoisan et al. Nov 2000 A
6152912 Jansen et al. Nov 2000 A
6159230 Samuels Dec 2000 A
6161547 Barbut Dec 2000 A
6165199 Barbut Dec 2000 A
6176844 Lee Jan 2001 B1
6197016 Fourkas et al. Mar 2001 B1
6206868 Parodi Mar 2001 B1
6210370 Chi-Sing et al. Apr 2001 B1
6234971 Jang May 2001 B1
6254628 Wallace et al. Jul 2001 B1
6258080 Samson Jul 2001 B1
6270477 Bagaoisan et al. Aug 2001 B1
6277139 Levinson et al. Aug 2001 B1
6287319 Aboul-Hosn et al. Sep 2001 B1
6295989 Connors, III Oct 2001 B1
6295990 Lewis et al. Oct 2001 B1
6306106 Boyle Oct 2001 B1
6306163 Fitz Oct 2001 B1
6364900 Heuser Apr 2002 B1
6368316 Jansen et al. Apr 2002 B1
6368344 Fitz Apr 2002 B1
6379325 Benett et al. Apr 2002 B1
6383172 Barbut May 2002 B1
6413235 Parodi Jul 2002 B1
6423032 Parodi Jul 2002 B2
6423086 Barbut et al. Jul 2002 B1
6428531 Visuri et al. Aug 2002 B1
6435189 Lewis et al. Aug 2002 B1
6436087 Lewis et al. Aug 2002 B1
6454741 Muni et al. Sep 2002 B1
6458151 Saltiel Oct 2002 B1
6464664 Jonkman et al. Oct 2002 B1
6481439 Lewis et al. Nov 2002 B1
6482172 Thramann Nov 2002 B1
6482217 Pintor et al. Nov 2002 B1
6508824 Flaherty et al. Jan 2003 B1
6517520 Chang et al. Feb 2003 B2
6527746 Oslund et al. Mar 2003 B1
6533800 Barbut Mar 2003 B1
6540712 Parodi et al. Apr 2003 B1
6544276 Azizi Apr 2003 B1
6549800 Atalar et al. Apr 2003 B1
6551268 Kaganov et al. Apr 2003 B1
6555057 Barbut et al. Apr 2003 B1
6562049 Norlander et al. May 2003 B1
6562052 Nobles et al. May 2003 B2
6582390 Sanderson Jun 2003 B1
6582396 Parodi Jun 2003 B1
6582448 Boyle et al. Jun 2003 B1
6595953 Coppi et al. Jul 2003 B1
6595980 Barbut Jul 2003 B1
6605074 Zadno-Azizi et al. Aug 2003 B2
6612999 Brennan et al. Sep 2003 B2
6623471 Barbut Sep 2003 B1
6623491 Thompson Sep 2003 B2
6623518 Thompson et al. Sep 2003 B2
6626886 Barbut Sep 2003 B1
6632236 Hogendijk Oct 2003 B2
6635070 Leeflang et al. Oct 2003 B2
6638243 Kupiecki Oct 2003 B2
6638245 Miller et al. Oct 2003 B2
6641573 Parodi Nov 2003 B1
6645160 Heesch Nov 2003 B1
6645222 Parodi et al. Nov 2003 B1
6652480 Imran et al. Nov 2003 B1
6656152 Putz Dec 2003 B2
6663650 Sepetka et al. Dec 2003 B2
6663652 Daniel et al. Dec 2003 B2
6679893 Tran Jan 2004 B1
6682505 Bates et al. Jan 2004 B2
6685722 Rosenbluth et al. Feb 2004 B1
6702782 Miller et al. Mar 2004 B2
6711436 Duhaylongsod Mar 2004 B1
6719717 Johnson et al. Apr 2004 B1
6730104 Sepetka et al. May 2004 B1
6733517 Collins May 2004 B1
6749627 Thompson et al. Jun 2004 B2
6755847 Eskuri Jun 2004 B2
6758854 Butler et al. Jul 2004 B1
6764464 McGuckin, Jr. et al. Jul 2004 B2
6790204 Zadno-Azizi et al. Sep 2004 B2
6824545 Sepetka et al. Nov 2004 B2
6827730 Leschinsky Dec 2004 B1
6837881 Barbut Jan 2005 B1
6840949 Barbut Jan 2005 B2
6849068 Bagaoisan et al. Feb 2005 B1
6855136 Dorros et al. Feb 2005 B2
6884235 McGuckin, Jr. et al. Apr 2005 B2
6902540 Dorros et al. Jun 2005 B2
6905490 Parodi Jun 2005 B2
6905505 Nash et al. Jun 2005 B2
6908474 Hogendijk et al. Jun 2005 B2
6929632 Nita et al. Aug 2005 B2
6929634 Dorros et al. Aug 2005 B2
6936060 Hogendijk et al. Aug 2005 B2
6958059 Zadno-Azizi Oct 2005 B2
6960189 Bates et al. Nov 2005 B2
6972030 Lee et al. Dec 2005 B2
7001400 Modesitt et al. Feb 2006 B1
7004924 Brugger et al. Feb 2006 B1
7004931 Hogendijk Feb 2006 B2
7004952 Nobles et al. Feb 2006 B2
7022100 Aboul-Hosn et al. Apr 2006 B1
7029488 Schonholz et al. Apr 2006 B2
7033336 Hogendijk Apr 2006 B2
7033344 Imran Apr 2006 B2
7048758 Boyle et al. May 2006 B2
7063714 Dorros et al. Jun 2006 B2
7083594 Coppi Aug 2006 B2
7104979 Jansen et al. Sep 2006 B2
7108677 Courtney et al. Sep 2006 B2
7144386 Korkor et al. Dec 2006 B2
7150712 Buehlmann et al. Dec 2006 B2
7152605 Khairkhahan et al. Dec 2006 B2
7166088 Heuser Jan 2007 B2
7169165 Belef et al. Jan 2007 B2
7172621 Theron Feb 2007 B2
7223253 Hogendijk May 2007 B2
7232452 Adams et al. Jun 2007 B2
7250042 Kataishi et al. Jul 2007 B2
7306585 Ross Dec 2007 B2
7309334 von Hoffmann Dec 2007 B2
7367982 Nash et al. May 2008 B2
7374560 Ressemann et al. May 2008 B2
7374561 Barbut May 2008 B2
7384412 Coppi Jun 2008 B2
7402151 Rosenman et al. Jul 2008 B2
7422579 Wahr et al. Sep 2008 B2
7458980 Barbut Dec 2008 B2
7497844 Spear et al. Mar 2009 B2
7524303 Don Michael et al. Apr 2009 B1
7534250 Schaeffer et al. May 2009 B2
7731683 Jang et al. Jun 2010 B2
7766049 Miller et al. Aug 2010 B2
7766820 Core Aug 2010 B2
7806906 Don Michael Oct 2010 B2
7815626 McFadden et al. Oct 2010 B1
7842065 Belef et al. Nov 2010 B2
7867216 Wahr et al. Jan 2011 B2
7905856 McGuckin, Jr. et al. Mar 2011 B2
7905877 Jimenez et al. Mar 2011 B1
7909812 Jansen et al. Mar 2011 B2
7927309 Palm Apr 2011 B2
7927347 Hogendijk et al. Apr 2011 B2
7972308 Putz Jul 2011 B2
7998104 Chang Aug 2011 B2
8029533 Bagaoisan et al. Oct 2011 B2
8052640 Fiorella et al. Nov 2011 B2
8066757 Ferrera et al. Nov 2011 B2
8142413 Root et al. Mar 2012 B2
RE43300 Saadat et al. Apr 2012 E
8152782 Jang et al. Apr 2012 B2
8157760 Criado et al. Apr 2012 B2
8181324 McFadden et al. May 2012 B2
8221348 Hackett et al. Jul 2012 B2
8231600 von Hoffmann Jul 2012 B2
8252010 Raju et al. Aug 2012 B1
8292850 Root et al. Oct 2012 B2
8343089 Chang Jan 2013 B2
8414516 Chang Apr 2013 B2
8545552 Garrison et al. Oct 2013 B2
8574245 Garrison et al. Nov 2013 B2
8870805 Chang Oct 2014 B2
8961549 Conn Feb 2015 B2
9126018 Garrison Sep 2015 B1
9241699 Kume et al. Jan 2016 B1
20010044598 Parodi Nov 2001 A1
20010049486 Evans et al. Dec 2001 A1
20010049517 Zadno-Azizi et al. Dec 2001 A1
20020087119 Parodi Jul 2002 A1
20020128679 Turovskiy et al. Sep 2002 A1
20020133111 Shadduck Sep 2002 A1
20020151922 Hogendijk et al. Oct 2002 A1
20020156455 Barbut Oct 2002 A1
20020156460 Ye et al. Oct 2002 A1
20020165598 Wahr et al. Nov 2002 A1
20020173815 Hogendijk et al. Nov 2002 A1
20020183783 Shadduck Dec 2002 A1
20030040762 Dorros et al. Feb 2003 A1
20030065356 Tsugita et al. Apr 2003 A1
20030069468 Bolling et al. Apr 2003 A1
20030078562 Makower et al. Apr 2003 A1
20030186203 Aboud Oct 2003 A1
20030212304 Lattouf Nov 2003 A1
20030212384 Hayden Nov 2003 A1
20040019322 Hoffmann Jan 2004 A1
20040059243 Flores et al. Mar 2004 A1
20040116878 Byrd et al. Jun 2004 A1
20040133232 Rosenbluth et al. Jul 2004 A1
20040138608 Barbut et al. Jul 2004 A1
20040181150 Evans et al. Sep 2004 A1
20040210194 Bonnette et al. Oct 2004 A1
20050004553 Douk Jan 2005 A1
20050065467 Pudelko et al. Mar 2005 A1
20050090802 Connors et al. Apr 2005 A1
20050131453 Parodi Jun 2005 A1
20050154344 Chang Jul 2005 A1
20050154349 Renz et al. Jul 2005 A1
20050209559 Thornton et al. Sep 2005 A1
20050273051 Coppi Dec 2005 A1
20060058836 Bose et al. Mar 2006 A1
20060058837 Bose et al. Mar 2006 A1
20060058838 Bose et al. Mar 2006 A1
20060089618 McFerran et al. Apr 2006 A1
20060106338 Chang May 2006 A1
20060135961 Rosenman et al. Jun 2006 A1
20060200191 Zadno-Azizi Sep 2006 A1
20060271098 Peacock Nov 2006 A1
20070021778 Carly Jan 2007 A1
20070073264 Stedman et al. Mar 2007 A1
20070173784 Johansson et al. Jul 2007 A1
20070197956 Le et al. Aug 2007 A1
20070198028 Miloslavski et al. Aug 2007 A1
20070198049 Barbut Aug 2007 A1
20080058839 Nobles et al. Mar 2008 A1
20080082107 Miller et al. Apr 2008 A1
20080140010 Kennedy et al. Jun 2008 A1
20080177245 Mesallum Jul 2008 A1
20080200946 Braun et al. Aug 2008 A1
20080255475 Kondrosky et al. Oct 2008 A1
20090018455 Chang Jan 2009 A1
20090024072 Criado et al. Jan 2009 A1
20090030400 Bose et al. Jan 2009 A1
20090198172 Garrison et al. Aug 2009 A1
20090254166 Chou et al. Oct 2009 A1
20090299393 Martin et al. Dec 2009 A1
20100004607 Wilson et al. Jan 2010 A1
20100030186 Stivland Feb 2010 A1
20100042118 Garrison et al. Feb 2010 A1
20100049147 Tanikawa et al. Feb 2010 A1
20100063479 Merdan et al. Mar 2010 A1
20100063480 Shireman Mar 2010 A1
20100094330 Barbut Apr 2010 A1
20100114017 Lenker et al. May 2010 A1
20100145308 Layman et al. Jun 2010 A1
20100185216 Garrison et al. Jul 2010 A1
20100204672 Lockhart et al. Aug 2010 A1
20100204684 Garrison et al. Aug 2010 A1
20100217276 Garrison et al. Aug 2010 A1
20100228269 Garrison et al. Sep 2010 A1
20100256600 Ferrera Oct 2010 A1
20100280431 Criado et al. Nov 2010 A1
20100318097 Ferrera et al. Dec 2010 A1
20110004147 Renati et al. Jan 2011 A1
20110009875 Grandfield et al. Jan 2011 A1
20110034986 Chou et al. Feb 2011 A1
20110087147 Garrison et al. Apr 2011 A1
20110112567 Lenker et al. May 2011 A1
20110125131 Chang May 2011 A1
20110125181 Brady et al. May 2011 A1
20110152760 Parker Jun 2011 A1
20110166496 Criado et al. Jul 2011 A1
20110166497 Criado et al. Jul 2011 A1
20110238041 Lim et al. Sep 2011 A1
20120095485 Cully et al. Apr 2012 A1
20120109044 Santamore et al. May 2012 A1
20120179097 Cully et al. Jul 2012 A1
20120238956 Yamada et al. Sep 2012 A1
20120310212 Fischell et al. Dec 2012 A1
20130035628 Garrison et al. Feb 2013 A1
20130172852 Chang Jul 2013 A1
20130184735 Fischell et al. Jul 2013 A1
20130197621 Ryan et al. Aug 2013 A1
20130281788 Garrison Oct 2013 A1
20140031682 Renati et al. Jan 2014 A1
20140031925 Garrison et al. Jan 2014 A1
20140046297 Shimada et al. Feb 2014 A1
20140046346 Hentges et al. Feb 2014 A1
20140058414 Garrison et al. Feb 2014 A1
20140135661 Garrison et al. May 2014 A1
20140155783 Starksen et al. Jun 2014 A1
20140236120 Tsai et al. Aug 2014 A1
20140257018 Farnan Sep 2014 A1
20140257186 Kerr Sep 2014 A1
20140296769 Hyde et al. Oct 2014 A1
20140296868 Garrison et al. Oct 2014 A1
20140371653 Criado et al. Dec 2014 A1
20150025616 Chang Jan 2015 A1
20150080942 Garrison et al. Mar 2015 A1
20150141760 Chou et al. May 2015 A1
20150150562 Chang Jun 2015 A1
20150173782 Garrison et al. Jun 2015 A1
20150174368 Garrison et al. Jun 2015 A1
20150327843 Garrison Nov 2015 A1
20160008025 Gupta et al. Jan 2016 A1
20160128688 Garrison et al. May 2016 A1
20160158044 Chou et al. Jun 2016 A1
20160158502 Kume et al. Jun 2016 A1
20160166804 Garrison et al. Jun 2016 A1
20160271315 Chang Sep 2016 A1
20160271316 Criado et al. Sep 2016 A1
20160279379 Chang Sep 2016 A1
20160296690 Kume et al. Oct 2016 A1
20170043141 Kume et al. Feb 2017 A1
20170136212 Garrison et al. May 2017 A1
20170209260 Garrison et al. Jul 2017 A1
20170312491 Ryan et al. Nov 2017 A1
20170354523 Chou et al. Dec 2017 A1
20170354803 Kume et al. Dec 2017 A1
20170361072 Chou et al. Dec 2017 A1
20170368296 Chang Dec 2017 A1
20180008294 Garrison et al. Jan 2018 A1
20180154063 Criado et al. Jun 2018 A1
20180185614 Garrison et al. Jul 2018 A1
20180289884 Criado et al. Oct 2018 A1
20190105439 Criado et al. Apr 2019 A1
20190150916 Hentges et al. May 2019 A1
20190175885 Kume et al. Jun 2019 A1
20190231962 Criado et al. Aug 2019 A1
20190254680 Chang Aug 2019 A1
20190262530 Criado et al. Aug 2019 A1
20190269538 Chou et al. Sep 2019 A1
20190350568 Garrison Nov 2019 A1
20190388654 Chou et al. Dec 2019 A1
20200009406 Garrison et al. Jan 2020 A1
20200015826 Chang Jan 2020 A1
20200016321 Criado et al. Jan 2020 A1
20200038576 Garrison et al. Feb 2020 A1
20200054871 Ryan et al. Feb 2020 A1
20200108221 Chang Apr 2020 A1
20200113587 Garrison et al. Apr 2020 A1
20200170637 Garrison et al. Jun 2020 A1
20200282127 Garrison et al. Sep 2020 A1
20200297912 Criado et al. Sep 2020 A1
20200375728 Garrison et al. Dec 2020 A1
20200375729 Garrison et al. Dec 2020 A1
20200390438 Garrison et al. Dec 2020 A1
20200397446 Chang Dec 2020 A1
20210205571 Chang Jul 2021 A1
20210212679 Hentges et al. Jul 2021 A1
20210228847 Kume et al. Jul 2021 A1
20210251634 Chang Aug 2021 A1
20210290213 Garrison Sep 2021 A1
20210290257 Garrison et al. Sep 2021 A1
20210299343 Criado et al. Sep 2021 A1
20210307945 Chou et al. Oct 2021 A1
Foreign Referenced Citations (36)
Number Date Country
101267781 Sep 2008 CN
102223909 Oct 2011 CN
102006039236 Feb 2008 DE
0427429 May 1991 EP
1440663 Jul 2004 EP
H02-71764 Mar 1990 JP
H04-263870 Sep 1992 JP
H7-148264 Jun 1995 JP
2003-522560 Jul 2003 JP
2005-500138 Jan 2005 JP
2007007042 Jan 2007 JP
2009-535084 Oct 2009 JP
2013-048881 Mar 2013 JP
WO-9505209 Feb 1995 WO
WO-9838930 Sep 1998 WO
WO-9945835 Sep 1999 WO
WO-0032266 Jun 2000 WO
WO-0076390 Dec 2000 WO
WO-0115767 Mar 2001 WO
WO-0158365 Aug 2001 WO
WO-0232495 Apr 2002 WO
WO-03018085 Mar 2003 WO
WO-03090831 Nov 2003 WO
WO-2004006803 Jan 2004 WO
WO-2005051206 Jun 2005 WO
WO-2006126642 Nov 2006 WO
WO-2007046348 Apr 2007 WO
WO-2007125488 Nov 2007 WO
WO-2008123521 Oct 2008 WO
WO-2008144587 Nov 2008 WO
WO-2009012473 Jan 2009 WO
WO-2009099764 Aug 2009 WO
WO-2009100210 Aug 2009 WO
WO-2010075445 Jul 2010 WO
WO-2010075565 Jul 2010 WO
WO-2012047803 Apr 2012 WO
Non-Patent Literature Citations (60)
Entry
U.S. Appl. No. 14/227,585, filed Mar. 27, 2014, US 2014-0296769.
U.S. Appl. No. 15/049,637, filed Feb. 22, 2016, US 2016-0242764.
U.S. Appl. No. 15/141,060, filed Apr. 28, 2016, US 2016-0317288.
U.S. Appl. No. 15/399,638, filed Jan. 5, 2017, US 2017-0209260.
U.S. Appl. No. 15/641,966, filed Jul. 5, 2017, US 2017-0296798.
U.S. Appl. No. 15/901,502, filed Feb. 21, 2018, US 2018-0235789.
U.S. Appl. No. 16/008,703, filed Jun. 14, 2018, US 2018-0289884.
U.S. Appl. No. 16/056,208, filed Aug. 6, 2018, US 2019-0175885.
U.S. Appl. No. 16/148,849, filed Oct. 1, 2018, US 2019-0269538.
U.S. Appl. No. 16/171,784, filed Oct. 26, 2018, US 2019-0125512.
U.S. Appl. No. 16/177,716, filed Nov. 1, 2018, US 2019-0150916.
U.S. Appl. No. 16/256,229, filed Jan. 24, 2019, US 2019-0254680.
U.S. Appl. No. 16/377,663, filed Apr. 8, 2019, US 2019-0231962.
U.S. Appl. No. 16/410,485, filed May 13, 2019, US 2019-0262530.
PCT/US18/40264, filed Jun. 29, 2018, WO 2019/010077.
PCT/US18/57789, filed Oct. 26, 2018, WO 2019/089385.
Adami, M.D., et al., (2002) “Use of the Parodi Anti-Embolism System in Carotid Stenting: Italian Trial Results” J Endovasc Ther 9:147-154.
Bergeron et al. (1999). “Percutaneous stenting of the internal carotid artery: the European Cast I Study” J. Endovasc. Surg. 6:155-159.
Bergeron et al. (2008) MEET Presentation, Cannes, French Riviera “Why I do not use routine femoral access for CAS”. 12 pages.
Bergeron P. et al. (1996) “Recurrent Carotid Disease: Will Stents be an alternative to surgery?” J Endovasc Surg; 3: 76-79.
Bourekas, E. C., A. P. Slivka, et al. (2004). “Intraarterial thrombolytic therapy within 3 hours of the onset of stroke.” Neurosurgery 54(1): 39-44; discussion 44-6.
Cohen et al., “A reappraisal of the common carotid artery as an access site in interventional procedures for acute stroke therapies”, Case Reports, Journal of Clinical Neuroscience 19 (2012) pp. 323-326.
Criado et al. (1997) “Evolving indications for and early results of carotid artery stenting” Am. J. Surg.; 174:111-114.
Diederich et al. (2004) “First Clinical experiences with an endovascular clamping system for neuroprotection during carotid stenting” Eur. J. Vase. Endovasc. Surg. 28:629-633.
Diethrich et al., (1996). “Percutaneous techniques for endoluminal carotid interventions” J. Endovasc. Surg. 3:182-202.
Diethrich, E. B. (2004). The Direct Cervical Carotid Artery Approach. Carotid Artery Stenting: Current Practice and Techniques. N. Al-Mubarak, G. S. Roubin, S. Iyer and J. Vitek. Philadephia, Lippincott Williams & Wilkins: Chapter 11. pp. 124-136.
Feldtman, R. W., C. J. Buckley, et al. (2006). “How I do it: cervical access for carotid artery stenting.” Am J Surg 192(6): 779-81.
Fiorella, D., M. Kelly, et al. (2008). “Endovascular Treatment of Cerebral Aneurysms.” Endovascular Today Jun. 2008. pp. 53-64.
Frazee, J. G. and X. Luo (1999). “Retrograde transvenous perfusion.” Crit Care Clin 15(4): 777-88, vii.
Frazee, J. G., X. Luo, et al. (1998). “Retrograde transvenous neuroperfusion: a back door treatment for stroke.” Stroke 29(9): 1912-6.
Goldstein “Acute Ischemic Stroke Treatment in 2007” Circ 116:1504-1514 (2007).
Gray et al. (2007) “The CAPTURE registry: Results of carotid stenting with embolic protection in the post approval setting” Cath. Cardovasc. Interven. 69:341-348.
Henry et al. (1999) “Carotid stenting with cerebral protection: First clinical experience using the PercuSurge GuardWire System” J. Endovasc. Surg. 6:321-331.
Hoffer et al. “Percutaneous Arterial Closure Devices” J. Vasc. Interv. Radiol. 14:865-885 (2003).
Howell, M., K. Doughtery, et al. (2002). “Percutaneous repair of abdominal aortic aneurysms using the AneuRx stent graft and the percutaneous vascular surgery device.” Catheter Cardiovasc Interv 55(3): 281-7.
Koebbe, C. J., E. Veznedaroglu, et al. (2006). “Endovascular management of intracranial aneurysms: current experience and future advances.” Neurosurgery 59(5 Suppl 3): S93-102; discussion S3-13.
Luebke, T et al. (2007) “Meta-analysis of randomized trials comparing carotid endarterectomy and endovascular treatment” Eur. J. Vasc. Endovasc. Surg. 34:470-479.
MacDonald, S. (2006) “Is there any evidence that cerebral protection is beneficial?” J. Cardiovasc. Surg. 47:127-36.
Mas et al. (2006) “Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis” NEJM 355:1660-71.
MomaPresn (AET) 2002 Biamino, G; MO.MA as a distal protective device, University of Leipzig—Heart Center Department of Clinical and Interventional; Angiology Leipzig, Germany; 2002. 37 pages.
Nesbit, G. M., G. Luh, et al. (2004). “New and future endovascular treatment strategies for acute ischemic stroke.” J Vasc Interv Radiol 15(1 Pt 2): S103-10.
Nii, K., K. Kazekawa, et al. (2006). “Direct carotid puncture for the endovascular treatment of anterior circulation aneurysms.” AJNR Am J Neuroradiol 27(7): 1502-4.
Ouriel, K., R. K. Greenberg, et al. (2001). “Hemodynamic conditions at the carotid bifurcation during protective common carotid occlusion.” J Vase Surg 34(4): 577-80.
Parodi et al. (2000). “Initial evaluation of carotid angioplasty and stenting with three different cerebral protection devices” J. Vasc. Surg. 32:1127-1136.
Parodi, J. C., L. M. Ferreira, et al. (2005). “Cerebral protection during carotid stenting using flow reversal.” J Vasc Surg 41(3): 416-22.
Perez-Arjona, E. A., Z. DelProsto, et al. (2004). “Direct percutaneous carotid artery stenting with distal protection: technical case report.” Neurol Res 26(3): 338-41.
Reekers, J. A. (1998). “A balloon protection sheath to prevent peripheral embolization during aortoiliac endovascular procedures.” Cardiovasc Intervent Radiol 21(5): 431-3.
Reimers et al. (2005). “Proximal endovascular flow blockage for cerebral protection during carotid artery stenting: Results froma prospective multicenter registry” J. Endovasc. Ther. 12:156-165.
Ribo, M., C. Molina, et al. (2008). “Buying Time for Recanalization in Acute Stroke: Arterial Blood Infusion Beyond the Occluding Clot as a Neuroprotective Strategy.” J Neuroimaging. 4 pages.
Ross, I. B. and G. D. Luzardo (2006). “Direct access to the carotid circulation by cut down for endovascular neuro-interventions.” Surg Neurol 65(2): 207-11; discussion 211.
Stejskal, et al., “Experience of 500 Cases of Neurophysiological Monitoring in Carotid Endarterectomy”, Acta Neurochir, 2007, 149:681-689.
Theron, et al. “New Triple Coaxial Catheter System for Carotid Angioplasty with Cerebral Protection.”. AJNR 11:869-874, Sep./Oct. 1990. 0195-6108/90/1106-0869. American Society of Neurology.
U.S. Appl. No. 16/250,825, filed Jan. 17, 2019, US 2019-0350568.
U.S. Appl. No. 16/281,311, filed Feb. 21, 2019, US 2019-0388654.
U.S. Appl. No. 16/297,348, filed Mar. 8, 2019, US 2020-0038576.
U.S. Appl. No. 16/299,524, filed Mar. 12, 2019, US 2019-0366070.
U.S. Appl. No. 16/353,492, filed Mar. 14, 2019, US 2020-0009406.
U.S. Appl. No. 16/530,783, filed Aug. 2, 2019, US 2020-0054871.
U.S. Appl. No. 16/581,034, filed Sep. 24, 2019, US 2020-0015826.
U.S. Appl. No. 16/581,061, filed Sep. 24, 2019, US 2020-0016321.
Related Publications (1)
Number Date Country
20200171277 A1 Jun 2020 US
Provisional Applications (6)
Number Date Country
62083128 Nov 2014 US
62075169 Nov 2014 US
62075101 Nov 2014 US
62046112 Sep 2014 US
62029799 Jul 2014 US
61919945 Dec 2013 US
Continuations (4)
Number Date Country
Parent 15728915 Oct 2017 US
Child 16544083 US
Parent 15299146 Oct 2016 US
Child 15728915 US
Parent 15050039 Feb 2016 US
Child 15299146 US
Parent 14569365 Dec 2014 US
Child 15050039 US